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Abstract
Interactions between leukocytes and vascular endothelial cells
are mediated by a complex set of membrane adhesion mole-
cules which transduce bi-directional signals in both cell types.
Endothelium of thecerebral blood vessels,whichconstitutethe
blood–brain barrier, strictly controls adhesion and trafﬁcking of
leukocytes into the brain. Investigating signaling pathways
triggeredbytheengagementofadhesionmoleculesexpressed
onbrainendothelialcells,wepreviouslydocumentedtheroleof
ICAM-1 in activation of the tyrosine phosphorylation of several
actin-binding proteins and subsequent rearrangements of the
actincytoskeleton.Inthepresentstudy,weshowthat,whereas
PECAM-1 is known to control positively the trans-endothelial
migration of leukocytes via homophilic interactions between
leukocytes and endothelial cells, PECAM-1 engagement on
brain endothelial surface unexpectedly counteracts the ICAM-
1-induced tyrosine phosphorylation of cortactin and rear-
rangements of the actin cytoskeleton. We present evidence
that the PECAM-1-associated tyrosine phosphatase SHP-2 is
required for ICAM-1 signaling, suggesting that its activity might
crucially contribute to the regulation of ICAM-1 signaling by
PECAM-1. Our ﬁndings reveal a novel activity for PECAM-1
which, by counteracting ICAM-1-induced activation, could
directly contribute to limit activation and maintain integrity of
brain vascular endothelium.
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Leukocyte extravasation into tissues involves a complex set
of adhesion molecules at the surface of leukocytes and
vascular endothelial cells. Tethering or rolling of leukocytes
is followed by their ﬁrm adhesion to endothelium, their
locomotion (Schenkel et al. 2004) at the endothelial surface,
which itself precedes diapedesis (Butcher 1991). In the
central nervous system, brain endothelial cells are joined by
continuous tight junctions, constituting the blood–brain
barrier (BBB), which strictly limits leukocyte inﬁltration,
as well as drug access to the cerebral compartment.
Nevertheless, in pathological situations, such as multiple
sclerosis, viral or bacterial infections, numerous activated
lymphocytes, monocytes or neutrophils can cross the BBB
(Carson et al. 2006; Engelhardt 2006).
On the endothelial apical surface, ICAM-1 is a key
player in ﬁrm adhesion and locomotion steps. In addition,
PECAM-1, which is expressed in endothelial cells, mono-
cytes, neutrophils and speciﬁc T lymphocyte subsets, is
directly involved in diapedesis via homophilic interactions
between migrating leukocytes, particularly monocytes/neu-
trophils and endothelial intercellular junctions (Muller
et al. 1993). Paradoxically, however, gene deﬁciency for
PECAM-1 was recently found to increase the number of
activated leukocytes crossing the BBB, suggesting that
PECAM-1 might play a more complex role in leukocyte
extravasation than previously recognized (Graesser et al.
2002).
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signal transducers in leukocytes and endothelial cells, in as
much as leukocyte adhesion to endothelial cells as well as
antibody cross-linking were shown to activate multiple
signaling pathways in both cell types. Using brain endothel-
ial cell lines, we previously provided evidence that ICAM-1
antibody cross-linking led to an increase in intracellular Ca
2+
concentration, protein kinase C activation, phosphorylation
of cortactin and other actin-binding proteins by the Src
tyrosine kinase, activation of RhoA GTPase, and subsequent
rearrangements of the actin cytoskeleton (Durieu-Trautmann
et al. 1994; Greenwood et al. 2002; Carman and Springer
2004; Shaw et al. 2004; Yang et al. 2005; Millan et al.
2006). Besides, PECAM-1 has been abundantly documented
as a signaling receptor which can transduce either inhibitory
or stimulatory signals with cell-speciﬁcity, such as inhibition
of the antigen receptor signaling in T lymphocytes or
stimulation of the intracellular calcium level in endothelial
cells (Newman et al. 2001; Newman and Newman 2003).
However, no evidence to our knowledge has emerged on
how the two activated signaling pathways coupled to
ICAM-1 and PECAM-1 are integrated by endothelial cells
and to what extent they might contribute in a sequential and
coordinated manner to the endothelial response to leukocyte
adhesion. In the present study, we addressed the question
of a putative cross-talk between these two signaling
pathways by sequential antibody cross-linking of ICAM-1
and PECAM-1 at the surface of endothelial cells: this
experimental approach has been shown by us and others
to mimic leukocyte interaction with endothelial cells and to
allow the biochemical analysis of endothelial response to
leukocyte adhesion. The rat brain endothelial cell line
RBE4 was used here as a robust model of brain microvas-
cular endothelium (Schweitzer et al. 1997; Hoffmann et al.
2001); We report in the present study that PECAM-1
engagement unexpectedly down-regulated ICAM-1-induced
tyrosine phosphorylation of cortactin and rearrangements of
the actin cytoskeleton. The functional relevance of this
ﬁnding is discussed in terms of regulation of BBB integrity
in inﬂammatory situations.
Materials and methods
Abs and reagents
Mouse mAb to rat ICAM-1 (clone 1A29), Major Histocompatibility
Complex (MHC) class II (OX6) and Transferrin receptor (OX26)
were purchased from Serotec (Wiesbaden, Germany). Anti-PE-
CAM-1 mAb 4E8 and anti-ICAM-1 mAb 3H8 were kindly provided
by Dr Hickey (Darmouth Medical School, Hanover, NH, USA).
M20 polyclonal Abs to rat PECAM-1, anti-SHP2 and anti-RhoA
mAb were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA). Rabbit anti-mouse (RAM) Abs were from DaKo France
(Trappes, France). Anti-phosphotyrosine and -cortactin mAbs were
purchased from Upstate Biotechnology/Millipore (Billerica, MA,
USA). Calpeptin was purchased from Calbiochem (La Jolla, CA,
USA). Tetramethylrhodamine isothiocyanate-conjugated phalloidin
was purchased from Sigma–Aldrich (St Louis, MO, USA).
Endothelial cell lines
Theratbrainmicrovascularendothelial(RBE4)celllinewasproduced
by us and extensively characterized (Roux et al. 1994; Etienne-
Manneville et al. 2000). RBE4 cells were grown as previously
described(Etienne-Mannevilleet al.2000).Thehumanbonemarrow
microvascular endothelial (HBMEC) cell line (Schweitzer et al.
1997) was kindly provided by Dr B. Weksler (Weill Medical College
of Cornell University, New York). HBMECs were cultured as
previouslydescribed(Hoffmannet al.2001).Bothcelllinesmaintain
in culture a fully differentiated endothelial phenotype.
Generation of HBMEC stable transfectants: HBMECs were
transfected with either the pcDNA3.1-SHP-2 (human wild type) or
pcDNA3.1-DnSHP-2 (Dominant negative) or ‘‘empty’’ plasmid
(‘‘mock’’) kindly provided by Dr C. Nahmias (Rivard et al. 1995)
using the nucleofector system developed by Amaxa Inc (Gaithers-
burg, MD, USA). Brieﬂy, for optimal transfection of HBMECs, 10
6
cells were suspended in 100 lL of solution V provided by Amaxa in
the presence of 1.5 lg DNA, and subjected to electroporation using
the program U15 of the nucleofector system. Cells were replated in
complete medium containing 10% fetal calf serum. The day after
400 lg/mL active G418 (Invitrogen, Cergy Pontoise, France) were
added to the cells. In order to obtain clonal transfectants, selected
neomycin plates were split to obtain isolated colonies. The clones
and pools (containing multiple clones) were screened for SHP-2
expression by western blotting with speciﬁc anti-SHP2 antibodies.
One pool and several clones expressing the dominant negative form
of SHP-2 (HBMEC/Dn-SHP-2) or wild type SHP-2 (HBMEC/WT-
SHP-2) and one pool transfected with empty plasmid (HBMEC/
mock) were chosen for further studies. Stable transfectants were
maintained in G418 and passaged before attaining conﬂuence.
Ab cross-linking of ICAM-1 and PECAM-1
Conﬂuent endothelial cells were pre-incubated with serum- and
growth factor-free culture medium containing 100 U/mL IFN-c for
48 h, before Ab cross-linking of ICAM-1 and/or PECAM-1. This
treatment has been shown to increase signiﬁcantly the surface
expression of ICAM-1 in RBE4 cells and was thus included in the
ICAM-1 cross-linking procedure, as described (Etienne et al. 1998;
Etienne-Manneville et al. 2000; Greenwood et al. 2002). In
addition, it was also previously reported to induce MHC II surface
expression in the same cells (Etienne et al. 1999).
Ab cross-linking was performed in four sequential steps at 37C,
under a 5% CO2 atmosphere, as summarized in Table 1: (i) cells
were incubated for 15-min with serum-free medium alone (–) or
with anti-ICAM-1 antibody (5 or 10 lg/mL); (ii) after two washes
with serum-free medium alone to remove unbound antibodies, cells
were incubated for 10-min with medium alone (–) or with rabbit
anti-mouse (RAM 10 lg/mL) antibodies; (iii) cells were next
washed twice and incubated for 15-min with serum-free medium
alone (–), with anti-PECAM-1 antibody (10 lg/mL) or with an
isotype-matched anti-MHC II antibody (10 lg/mL); (iv) ﬁnally,
after two washes, cells were incubated for 10-min with medium
alone (–) or with RAM antibodies (10 lg/mL).
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control antibody was previously shown not only to bind to IFN-c-
activated RBE4 cells, but also to trigger signaling pathways in
RBE4 cells distinct from those activated by ICAM-1 cross-linking
(Durieu-Trautmann et al. 1994; Etienne et al. 1999; Greenwood
et al. 2002).
In order to inhibit SHP-2 phosphatase, endothelial cells (RBE-4
or HBMECs) were treated with 150 lg/mL of calpeptin (Calbio-
chem, La Jolla, CA, USA) for 30 min prior to ICAM-1 cross-
linking.
Immunoﬂuorescence analysis
Cells grown to conﬂuence on Permanox coverslips (Costar,
Corning, NY, USA), were starved in serum-and growth factor-free
medium for 24 h, and then treated as described above for antibody
cross-linking. F-actin staining was performed as previously des-
cribed (Etienne-Manneville et al. 2000) and ﬂuorescence images
were collected using a scanning confocal microscope (MCR. 1000;
Bio-Rad, Hercules, CA, USA). At least three independent experi-
ments were performed in triplicates.
Immunoprecipitations and western blotting analysis
Following treatments, cells were washed with ice-cold phosphate-
buffered saline and lysed for 30 min at 4C for – cortactin and
ICAM-1 experiments: in Nonidet P-40 buffer containing 10 mmol/L
Tris–HCl, pH 7.5, 140 mmol/L NaCl, 1% NP-40, 1 mmol/L
phenylmethylsulfonyl ﬂuoride, 1 mmol/L orthovanadate, 50 units/
mL aprotinin, 1 mmol/L EDTA, 2 lg/mL pepstatin, 2 lg/mL
leupeptin.
PECAM-1 experiments: cells were lysed in Nonidet P-40 buffer
containing 50 mmol/L Tris–HCl, pH 7.5, 250 mmol/L NaCl, 0.5%
NP-40, 5 mmol/L EDTA, 1 mmol/L CaCl2, 1 mmol/L MgCl2,
supplemented with the same protease inhibitors used in cortactin
lysis buffer.
Nuclei were discarded following centrifugation at 13 000 g for
10 min at 4C. Cleared lysates were incubated for 3 h at 4C with
speciﬁc Abs, then for 2 h with agarose beads which were pre-
incubated for 2 h with an excess of control mouse immuno-
globulins. Immunoprecipitates were collected by centrifugation at
1200 g and processed for western blotting analysis as previously
described (Etienne-Manneville et al. 2000). At least three inde-
pendent experiments were performed in triplicates.
RhoA activity assay
Cells were lysed in 50 mmol/LTris pH 7.5, 150 mmol/L NaCl, 10%
glycerol, 1% NP-40, 0.1% Triton X-100, 5 mmol/L MgCl2,
0.1 mmol/L phenylmethylsulfonyl ﬂuoride, 10 lg/mL leupeptine,
10 lg/mL aprotinin. Cleared lysates were incubated with bacterially
produced GST-RBD (Rhotekin) bound to glutathione–agarose beads
for 45 min at 4C, as described (Reid et al. 1996; Sander and
Collard 1999). The beads were washed three times with lysis buffer,
and then bound proteins were analyzed by SDS–PAGE and western
blotting as described (Etienne et al. 1998). At least three independ-
ent experiments were performed in triplicates.
Results
PECAM-1 cross-linking inhibits ICAM-1-induced actin
cytoskeleton rearrangements
In order to assess the existence of a putative cross-talk
between the signaling pathways coupled to ICAM-1 and
PECAM-1 in brain endothelial cells, we developed a
procedure of sequential antibody cross-linking of ICAM-1
and PECAM-1 (see Materials and methods) to mimic the
supposed sequence of events supporting leukocyte extrava-
sation.
We previously documented that ICAM-1 cross-linking at
the surface of the rat brain endothelial RBE4 cells lead to
actin cytoskeleton rearrangements through activation of
RhoA GTPase (Etienne et al. 1998; Adamson et al. 1999;
Etienne-Manneville et al. 2000; Yang et al. 2006). Here, we
conﬁrmed that, whereas polymerized actin was mainly
cortical in basal condition (incubation with Rabbit anti-
Mouse antibodies) (Fig. 1a), ICAM-1 cross-linking induced
the formation of numerous actin stress ﬁbers across RBE4
cells (Fig. 1b); this response was maintained over the entire
incubation period (50 min). By contrast, no stress ﬁber
formation was observed following PECAM-1 cross-linking
(Fig. 1c). Unexpectedly, we did not observe any stress ﬁber
formation following sequential antibody cross-linking of
ICAM-1 and PECAM-1 (Fig. 1d). As control, cross-linking
of ICAM-1 followed by incubation with buffer alone or with
the isotype-matched anti-MHC-II antibody (Fig. 1e) or anti-
transferrin antibody (not shown) or again with the same
anti-ICAM-1 antibody (not shown) did not affect the ICAM-
1-induced formation of stress ﬁbers. Similar results were
observed using the human microvascular endothelial cell line
HBMEC of peripheral origin (not shown). These results
indicate that PECAM-1 engagement drastically blocked the
Table 1 Experimental procedure for
sequential cross-linking of ICAM-1 and/or
PECAM-1 at the surface of cultured endo-
thelial cells
Steps 1 (15 min) 2 (10 min) 3 (15 min) 4 (10 min)
Conditions
BASAL – RAM – RAM
ICAM-1 a-ICAM-1 RAM – RAM
PECAM-1 – – a-PECAM-1 RAM
ICAM-1 + PECAM-1 (I + P) a-ICAM-1 RAM a-PECAM-1 RAM
PECAM-1 + ICAM-1 (P + I) a-PECAM-1 RAM a-ICAM-1 RAM
ICAM-1 + MHC-II a-ICAM-1 RAM a-MHC-II RAM
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and human endothelial cells.
Because actin stress ﬁber formation is known as a
RhoGTPase-mediated process, we evaluated this activity in
RBE4 cell extracts in the same conditions of ICAM-1 and/or
PECAM-1 antibody cross-linking. For that purpose, we used
a validated pull-down assay based on the speciﬁc interaction
between the activated GTP-bound RhoA (compared to the
non-activated GDP-bound RhoA) and the RhoA-binding
domain (RBD) of the RhoA effector Rhotekin fused to
glutathione-S-transferase (GST) (Reid et al. 1996; Sander
and Collard 1999). Following ICAM-1 cross-linking or
control treatment, cell extracts containing equal amounts of
RhoA protein (as conﬁrmed by western blotting: not shown)
were incubated with the the Rhotekin-GST fusion protein: a
large amount of retained (i.e. activated) RhoA was detected
following ICAM-1 cross-linking (Fig. 1f, lane b), compared
to basal conditions (Fig. 1f, lane a), conﬁrming our previous
ﬁnding that ICAM-1 cross-linking induces a strong activa-
tion of RhoA in RBE4 cells. PECAM-1 cross-linking per se
did not activate RhoA (Fig. 1f, lane c), but completely
inhibited ICAM-1-induced RhoA activation (Fig. 1f, lane d).
As a control, the irrelevant isotype-matched anti-MHC-II
antibody had no effect on ICAM-1 response (Fig. 1f, lane e).
These results provide further evidence that PECAM-1 cross-
linking affects the ICAM-1-induced cortical actin polymer-
ization by interfering with RhoA activation.
PECAM-1 cross-linking inhibits ICAM-1-induced
cortactin phosphorylation
Together with actin polymerization, we previously docu-
mented that ICAM-1 cross-linking strongly stimulated the
tyrosine kinase Src activity and tyrosine phosphorylation of
several actin-binding proteins, including cortactin. This
response was maintained over extended periods of time
(for at least 60 min) (Durieu-Trautmann et al. 1994; Etienne
et al. 1998; Etienne-Manneville et al. 2000). In order to
assess whether PECAM-1 engagement might affect ICAM-1-
induced cortactin phosphorylation, we performed the same
sequential antibody cross-linking of ICAM-1 and PECAM-1
at the surface of RBE4 cells.
As shown in Fig. 2, while ICAM-1 cross-linking strongly
enhanced cortactin tyrosine phosphorylation in RBE4 cells
(Fig. 2a, lanes b and c), PECAM-1 cross-linking, which had
no effect alone (Fig. 2a, lane d), markedly reduced ICAM-1-
induced cortactin phosphorylation (Fig. 2a, lane e). As a
(a)
(d)
(b)
(e)
(c)
(f)
Fig. 1 PECAM-1 cross-linking reverses ICAM-1-induced actin cyto-
skeleton rearrangements. Sequential cross-linking of ICAM-1 and/or
PECAM-1 was performed on IFN-c-treated RBE4 cells as described in
Material and methods. Panels (a–e) Cells were ﬁxed and actin was
stained by using 0.1 lg/mL of tetramethylrhodamine isothiocyanate-
labeled phalloidin. Panel (a) basal condition. Panel (b) ICAM-1 cross-
linking. Panel (c) PECAM-1 cross-linking. Panel (d) Sequential ICAM-1
and then PECAM-1 cross-linking. Panel (e) As a control, sequential
ICAM-1 and then MHC-II cross-linking. Panel (f) GST-Rhotekin pull-
down. Proteins were eluted with SDS-sample buffer, and resolved on
a 12% SDS–PAGE followed by immunoblotting with anti-RhoA speciﬁc
or anti-GST antibody. Lane a: basal condition; lane b: ICAM-1 cross-
linking; lane c: PECAM-1 cross-linking; lane d: sequential ICAM-1 and
then PECAM-1 cross-linking; lane e: sequential ICAM-1 and then
MHC-II cross-linking.
796 J.-P. Couty et al.
Journal Compilation  2007 International Society for Neurochemistry, J. Neurochem. (2007) 103, 793–801
 2007 The Authorscontrol, cross-linking of the IFN-c -induced MHC class II
proteins by an isotype-matched anti-MHC-II antibody
(Fig. 2a, lane f) or of transferrin receptors (not shown) did
not affect ICAM-1-induced cortactin phosphorylation. More-
over, similar results were observed using the non-brain
endothelial cell line HBMEC (Fig. 2b). Partial inhibition of
ICAM-1-induced cortactin phosphorylation was already
observed after only 5 min of PECAM-1 cross-linking (not
shown).
Furthermore, in order to assess whether PECAM-1 cross-
linking could not only reduce ICAM-1-mediated response in
RBE4 cells, but also prevent it, we then performed sequential
cross-linking of PECAM-1 and ICAM-1 in this order.
Figure 2c reveals that inhibition of ICAM-1-induced cortac-
tin phosphorylation was even more drastic in this case
(Fig. 2c, lanes P + I) than when PECAM-1 cross-linking
followed ICAM-1 cross-linking as above (Fig. 2c, lanes
I + P).
Altogether, these ﬁndings support the conclusion that
PECAM-1 engagement on the surface of brain (and non-
brain) endothelial cells drastically inhibits multiple ICAM-1
signaling pathways, including cortactin phosphorylation and
actin rearrangements.
The tyrosine phosphatase SHP-2 is at the crossroad
between ICAM-1 and PECAM-1-coupled signaling
pathways
The tyrosine phosphatase SHP-2, is known to bind to
activated PECAM-1. To gain insight into the molecular
mechanisms mediating the observed inhibition of ICAM-1
signaling by PECAM-1 cross-linking, we then tested the
hypothesis that SHP-2 might be involved in this process.
Following PECAM-1 antibody cross-linking, we consistently
observed a robust tyrosine phosphorylation of PECAM-1 and
its interaction with SHP-2 as shown in Fig. 3a (lane b); the
other known PECAM-1-interacting phosphatases SHP-1 and
SHIP were not detected in the endothelial cells used in this
study (data not shown).
Moreover, focusing on ICAM-1 signaling pathway, we
observed a slight but consistent increase in the amount of
SHP-2 in ICAM-1 immunoprecipitates following antibody
cross-linking, although we failed to detect any ICAM-1
phosphorylation (Fig. 3a, lane d): this result suggested a non-
conventional or indirect interaction between ICAM-1 and
SHP-2. Similar results were observed using HBMECs (not
shown). To further assess a functional role for SHP-2 in
ICAM-1-coupled signaling pathways, we established endot-
helial cell lines stably expressing a dominant negative form
of SHP-2 (Dn-SHP-2) or the wild type enzyme (WT-SHP-2)
as a control; for technical reasons, HBMECs were used in
this approach. Following antibody cross-linking of ICAM-1,
we observed that expression of Dn-SHP-2 abolished the
ICAM-1 induced tyrosine phosphorylation of cortactin
(Fig. 3b, lane h), pointing to SHP-2 as a positive regulator
of the Src-cortactin pathway in endothelial cells. By contrast,
over-expression of the wild type enzyme had no effect
(Fig. 3b, lane e), suggesting that endogenous SHP-2 activity
was sufﬁcient for a maximal stimulation of cortactin
phosphorylation by ICAM-1 cross-linking. Immunoblotting
with anti SHP-2 antibody (not shown) was used for control
of sample loading. Interestingly, calpeptin (Fig. 4a, lane e), a
known calpain inhibitor which was previously identiﬁed and
characterized as a selective inhibitor of SHP-2 activity
(Schoenwaelder et al. 2000; Gopalakrishnan et al. 2003)
(a) (c) (b)
Fig. 2 PECAM-1 cross-linking reverses ICAM-1-induced cortactin
phosphorylation. Sequential cross-linking of ICAM-1 and/or PECAM-1
was performed on IFN-c-treated RBE4 cells or HBMECs as described
in Material and methods. Immunoprecipitated proteins were eluted
with SDS-sample buffer, and resolved on 7.5% SDS-PAGE followed
by immunoblotting with anti-phosphotyrosine (4 G10) or anti-cortactin
antibodies. Panel (a) Cortactin immunoprecipitation using RBE4 cells.
Panel (b) Cortactin immunoprecipitation using HBMECs. Lane a: basal
condition; lanes b and c: ICAM-1 cross-linking (b, 5 lg/mL and c,
10 lg/mL of ICAM-1 antibodies); lane d: PECAM-1 cross-linking
(10 lg/mL); lane e: sequential ICAM-1 and then PECAM-1 (10 lg/mL
each) cross-linking; lane f: sequential ICAM-1 and then MHC class II
cross-linking (10 lg/mL each). Panel (c) PECAM-1 cross-linking pre-
vents ICAM-1-induced cortactin phosphorylation in RBE4 cells. Lane
a: basal condition; lane b: ICAM-1 cross-linking (10 lg/mL of ICAM-1
antibodies); lane e (duplicates): ICAM-1 cross-linking followed by
PECAM-1 cross-linking (I + P) (10 lg/mL antibodies); lane f (dupli-
cates): PECAM-1 cross-linking followed by ICAM-1 cross-linking
(P + I) (10 lg/mL antibodies).
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response to antibody cross-linking of ICAM-1 in RBE4 cells
(Fig. 4e) and in HBMECs (not shown).
In conclusion, the main ﬁndings of the current study are
summarized in Fig. 5: they demonstrate that SHP-2 is
positively involved in ICAM-1 signaling, upstream of the
tyrosine phosphorylation of cortactin by Src and of RhoA-
mediated actin cytoskeleton rearrangements. More import-
antly, our results show that PECAM-1 engagement, which
induces a strong interaction with SHP-2, drastically inhibits
these two distinct ICAM-1 activated pathways. Together,
these results suggest that SHP-2 might be a key player at the
crossroads between ICAM-1 and PECAM-1 signalings in
endothelial cells.
Discussion
We show in the present study that PECAM-1 engagement by
antibody cross-linking totally blocked ICAM-1-induced
activation of RhoA and subsequent changes in actin cyto-
skeleton, as well as tyrosine phosphorylation of cortactin in
rat brain endothelial cells. Moreover, these ﬁndings suggest
that the tyrosine phosphatase SHP-2, as an upstream
mediator of both PECAM-1 and ICAM-1 signaling path-
ways, might be a key player in the cross-talk identiﬁed here
between these pathways.
Accumulating evidence indicates that, beyond its ability to
contribute to the formation of ‘‘docking’’ sites for circulating
leucocytes (Barreiro et al. 2002; Carman et al. 2003),
ICAM-1 behaves as a signal transducer, activating multiple
signaling pathways in endothelial cells. ICAM-1 signaling in
(a)
(b)
Fig. 3 SHP-2 is recruited by cross-linked ICAM-1 and PECAM-1.
Panel (a) Cross-linking of ICAM-1 or PECAM-1 was performed on
IFN-c-treated RBE4 cells as described in Material and methods.
Immunoprecipitated proteins were eluted with SDS-sample buffer, and
resolved on 7.5% SDS-PAGE followed by immunoblotting with anti-
phosphotyrosine (4 G10) or anti-ICAM1 or PECAM-1 antibodies or
with anti-SHP-2 antibody. Lane a: basal condition; lane b: PECAM-1
cross-linking; lane c: basal condition; lane d: ICAM-1 cross-linking.
Panel (b) Sequential cross-linking of ICAM-1 and/or PECAM-1 was
performed on IFN-c-treated mock-transfected HBMECs or stably
expressing WT-SHP-2 or Dn-SHP-2 as described in Material and
methods. Immunoprecipitated proteins were eluted with SDS-sample
buffer, and resolved on 7.5% SDS-PAGE followed by immunoblotting
with anti-phosphotyrosine antibody (4 G10) or anti-cortactin antibody.
Lanes a, d, g: basal condition; lanes b, e, h: ICAM-1 cross-linking;
lanes c, f, i: sequential ICAM-1 and PECAM-1 cross-linking.
(a)
(b) (c)
(d) (e)
Fig. 4 The SHP-2 inhibitor calpeptin mimicks PECAM-1-induced re-
versal of ICAM-1 signaling. Panel (a) Sequential cross-linking of
ICAM-1 and/or PECAM-1 was performed on IFN-c-treated RBE4 cells
pre-incubated with or without the selective SHP-2 inhibitor calpeptin
(150 lg/mL) as described in Material and methods. Following cortactin
immunoprecipitation, immunoblotting with anti-phosphotyrosine anti-
bodies (clone 4 G10) or anti-cortactin antibodies detected tyrosine-
phosphorylated cortactin or total amount of cortactin, respectively.
Lanes a, d: basal condition; lanes b, e: ICAM-1 cross-linking; lanes c, f:
sequential ICAM-1 and PECAM-1 cross-linking. Panels (b–e) IFN-c-
treated RBE4 cells were treated or not with calpeptin (150 lg/mL for
30 min) prior to ICAM-1 cross-linking. Cells were ﬁxed and actin was
stained by using 0.1 lg/mL of tetramethylrhodamine isothiocyanate-
labeled phalloidin. Panel (b) Basal condition. Panel (c) ICAM-1 cross-
linking. Panel (d) Basal condition after calpeptin treatment. Panel (e)
ICAM-1 cross-linking after calpeptin treatment.
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endothelial migration of leucocytes to inﬂammation sites. We
previously identiﬁed multiple signaling pathways activated
in rat brain endothelial cell lines, following ICAM-1 cross-
linking or leukocyte adhesion. In particular, we demonstrated
activation of the tyrosine kinase Src and tyrosine phosphory-
lation of several cytoskeleton-associated proteins, including
cortactin (Etienne et al. 1998; Adamson et al. 1999; Etienne-
Manneville et al. 2000). In spite of the short C-terminal
domain of ICAM-1, which comprises 27 amino acids in rat
and 28 amino acids in human, biochemical studies have
demonstrated that ICAM-1 is capable of binding a number of
intracellular proteins in endothelial cells: the actin-binding
protein a-actinin, the microtubule-associated b-tubulin, the
enzyme glyceraldehyde-3-phosphate dehydrogenase and
ezrin, a linker between integral membrane proteins and the
actin-cytoskeleton (Federici et al. 1996; Celli et al. 2006). In
addition, it has been suggested that SHP-2 might associate
with tyrosine phosphorylated ICAM-1, even though ICAM-1
does not contain a bona ﬁde SHP-2 binding site, such as a
consensus immunoreceptor tyrosine-based inhibitory motif
(Pluskota et al. 2000; Wang et al. 2003). In the present
study, the moderate amount of SHP-2 bound to ICAM-1
(compared with SHP-2 bound to PECAM-1) following
antibody cross-linking may be related to a very low level of
ICAM-1 tyrosine phosphorylation (not detected here or in a
previous studies (Greenwood et al. 2003)) or may reﬂect
interaction with a putative non-conventional motif in the
ICAM-1 cytoplasmic domain. Alternatively, interaction
between ICAM-1 and SHP-2 might be indirect, via an
unidentiﬁed protein linker.
SHP-2 is known as an upstream mediator of multiple
signaling pathways, but contrasting data in various cell
systems present it either as a negative or a positive regulator
of RhoA and other pathways (Pluskota et al. 2000; Lacalle
et al. 2002; Wang et al. 2003; Kontaridis et al. 2004). Here
we showed that a dominant negative form of SHP-2 (Dn-
SHP-2) or calpeptin inhibition of SHP-2 enzymatic activity
largely inhibited the ICAM-1-mediated tyrosine phosphory-
lation of cortactin and actin stress ﬁber formation. These
results, summarized in Fig. 5, clearly establish that SHP-2 is
positively involved in ICAM-1 signaling in endothelial cells,
upstream of the Src-mediated tyrosine phosphorylation of
cortactin as well as RhoA-mediated actin cytoskeleton
rearrangements.
PECAM-1 has been convincingly shown to transduce
inhibitory signals in a variety of cell types, including
endothelial cells, through SHP-2 binding to a tyrosine-
phosphorylated immunoreceptor tyrosine-based inhibitory
motif in its cytoplasmic domain (Masuda et al. 1997;
Henshall et al. 2001; Patil et al. 2001; Cicmil et al. 2002;
Gratzinger et al. 2003; Jackson 2003; Newman and Newman
2003). The results of the present study showed that PECAM-
1 engagement concomitantly induced SHP-2 binding to
PECAM-1 and blocked the SHP-2-dependent phosphoryla-
tion of cortactin and rearrangements of the actin cytoskeleton
evoked by ICAM-1. This is to our knowledge the ﬁrst
evidence that PECAM-1 engagement can negatively regulate
the signaling pathways coupled to another leukocyte adhe-
sion molecule in endothelial cells. This observation strongly
suggests that leukocyte adhesion and transmigration trigger
in endothelial cells a complex set of interconnected positive
and negative signalings which cooperate for controlling the
dynamics of endothelial response. Although our study cannot
ﬁrmly establish a direct role for SHP-2 in PECAM-1-coupled
inhibition of ICAM-1 signaling, it is tempting to speculate
that activated PECAM-1, by efﬁciently recruiting SHP-2,
may sequester it away from ICAM-1 and inhibit RhoA and
Src activation. This hypothesis is in line with the interpret-
ation proposed for PECAM-1 inhibition of growth factor or
antigen receptor signaling pathways (Newman et al. 2001;
Newman and Newman 2003). Alternatively, other proteins
involved in the maintenance of endothelial junction integrity
such as b-o rc-catenin, PLC-c, which are also known to
interact with the cytosolic domain of PECAM-1, might be
involved in the regulatory loop identiﬁed here between
ICAM-1 and PECAM-1 (Ilan and Madri 2003). However, we
did not observe in the present study any detectable associ-
ation between PECAM-1 and b-o rc-catenin (not shown).
We and others provided compelling evidence that ICAM-
1-induced signaling and subsequent actin cytoskeleton
remodeling was directly involved in the process of trans-
Fig. 5 Cross-talk between ICAM-1 and PECAM-1-coupled signaling
pathways. SHP-2 is positively involved in ICAM-1 signaling, upstream
of the tyrosine phosphorylation of cortactin by Src and of RhoA-
mediated actin cytoskeleton rearrangements. In this study, we show
that PECAM-1 engagement, which induces a strong interaction with
SHP-2, drastically inhibits these two distinct ICAM-1 activated path-
ways. Together, we propose that SHP-2 might be a key player at the
crossroads between ICAM-1 and PECAM-1 signalings in endothelial
cells.
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mann et al. 1994; Greenwood et al. 2002; Carman and
Springer 2004; Shaw et al. 2004; Yang et al. 2005; Millan
et al. 2006). Pharmacological inhibition of ICAM-1 coupled
signalling pathways, using Rho kinase inhibitors or calcium
chelators, largely prevented the migration of activated
lymphocytes across RBE4 cells (Adamson et al. 1999;
Etienne-Manneville et al. 2000). Moreover, we demonstrated
that inhibition of Rho GTPases with protein prenyltransf-
erase inhibitors prevented leukocyte recruitment to the CNS
and attenuated clinical signs of disease in Experimental
Autoimmune Encephalomyelitis (Walters et al. 2002). Com-
plementary experiments demonstrated that the ICAM-1-
induced Src-cortactin pathway is essential for trans-endot-
helial migration of leukocytes (Yang et al. 2005, 2006).
Moreover, recent studies have demonstrated that leukocyte
adhesion promotes the remodeling of the apical endothelial
plasma membrane into projections that surround adherent
leukocytes (Carman and Springer 2004; Shaw et al. 2004;
Barreiro et al. 2005; Doulet et al. 2006). These structures,
referred to as endothelial docking structures or transmigra-
tory cups, are essential to promote ﬁrm adhesion and
extravasation of leukocytes through paracellular as well as
transcellular routes. Formation of these docking structures
results from the dynamic redistribution of several adhesion
molecules including ICAM-1 and actin polymerization. The
current study strongly suggests that PECAM-1 engagement
during paracellular extravasation of leukocytes, which has
been well-documented to contribute to leukocyte diapedesis,
may also regulate this process by limiting the ICAM-1
induced actin cytoskeleton rearrangements, downstream of
the formation of docking structures. Future studies will aim
at evaluating the functional relevance of these ﬁndings, by
evaluating the role of the PECAM-1 cytoplasmic domain and
associated signaling in regulation of leukocyte transmigration
across brain endothelial cells. In addition, because PECAM-1
is not present in endothelial docking structures, it will be
necessary to identify the cellular compartments where the
signalling cross-talk reported here may take place. It can be
hypothesized that caveolae or caveolin-rich microdomains
may facilitate the functional interaction between ICAM-1-
and PECAM-1 signalings in as much as PECAM-1 is present
in these structures whereas ICAM-1 was recently shown to
be recruited in similar structures following antibody cross-
linking (Millan et al. 2006; Viegas et al. 2006). Further
experiments will be required to substantiate this hypothesis.
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